GeneWiz, Beijing ACCB Biotech Partner on NGS-based Tests for Clinical Space | GenomeWeb

NEW YORK (GenomeWeb News) – GeneWiz and Beijing ACCB Biotech today said they are collaborating on next-generation sequencing-based tests for the clinical market.

The firms are partnering to develop, validate, and commercialize genetic tests "that deliver clinically relevant, medically actionable results," they said. GeneWiz will develop and validate genetic testing methods that ACCB will then qualify and register. Using those methods, it will then produce diagnostic kits.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.